Redefining Molecular Testing
QuantumCyte's QCPRECISE!™ NextGen Microdissection
Platform and Services
Redefining Molecular Testing
QuantumCyte's QCPRECISE!™ NextGen Microdissection
Platform and Services
QuantumCyte's QCPRECISE!™ NextGen Microdissection
Platform and Services
QuantumCyte's QCPRECISE!™ NextGen Microdissection
Platform and Services
The QCPRECISE!™ NextGen Microdissection Platform facilitates the precise capture of Nucleic Acids from Regions of Interest in FFPE tissues, resulting in a sample with elevated cellular purity for subsequent molecular testing.
Elevate Your Purity
Don't Think Total Yield, Think Yield From Targeted Tissue.
Access QuantumCyte™ Technology through our Service Lab.
Services for digitization through DNA or RNA purification
FFPE H&E stained sections on slides are Digitally or AI Annotated and the resulting JSON file is uploaded to QCPRECISE!™ PRINTMATCH™ Software. QCPRECISE!™ is agnostic to the Annotation platform.
The QCPRECISE!™ instrument in action. The QCPRECISE!™ instrument uses the Masking file to deposit a proprietary polymer on the tissue areas that are not the regions of interest.
Pre-Masked Regions of Interest/Tumor are show in dark purple.
Masking and Lysis of the tissue in the Regions of Interest is done on the slide. Tumor tissue is precisely removed and the Lysate is purified while the background tissue is blocked by the poylmer mask.
Nucleic Acid Purification of RNA or DNA from Lysate can be performed and used for Molecular Testing. Results in increased Purity of Nucleic Acids from Region of Interest/Tumor.
Get Early access to the QCPRECISE!™ Platform
Contact us to apply to participate in our
Early Access Program
Publications and Posters
QuantumCyte unveils QCPRECISE!™ platform at AMP 2023.
We are excited to showcase our latest posters at USCAP. Join our CEO, John Butler March 23-28th.
In 2007 John Butler's, CEO and Founder of Quantumcyte™, wife was diagnosed with late stage metastatic carcinoid cancer, a rare incurable untreatable disease at that time.
Since then John has devoted his life to the development of a technology that would deliver a set of capabilities to study cancer in a very unique way. Armed with a knack for developing products that answer complex biological questions, an amazing network of scientists, engineers, computational biologists, business development professionals, and a supportive network of investors and scientific advisors, John teamed up with Quantumcyte’s CTO and Founder, Dr. Bidhan Chaudhuri.
Together John and Bidhan embarked on a journey to develop a product that would enable cancer research and clinical communities to study and diagnose cancer a very unique way. The result of their efforts is the creation of a product called QCPrecise!™. QCPrecise!™ represents a cutting edge fusion of AI based digital pathology and molecular analysis. This innovative workflow not only generates unique translational data but also introduces novel clinical workflows that tackle the challenge of cancer’s heterogeneity. It empowers us to develop groundbreaking clinical tests for cancer, metastatic disease, and other solid tissue diseases.
Throughout this journey, the Quantumcyte™ team has cultivated strong relationships with major clinical labs in hospitals, translation research institutions in academia, and major pharma companies all excited to use the QCPrecise!™ system to advance their critical work.
CEO/CSO
CTO
CCO
VP Business Development
Lab Manager
Digital Marketing & Design
Copyright © 2024 QuantumCyte - All Rights Reserved.
Powered by GoDaddy